After corrections for multiple comparisons, neither the mean level of NKCC1 mRNA (Figure 1A) nor KCC2 mRNA (Figure 1B) was significantly altered in subjects with schizophrenia (paired ANCOVA, both F1,38<3.8 and P > .43; unpaired ANCOVA, both F1,75<4.1 and P > .33). For the chloride transporter–related kinases, group differences in gene expression levels were not significant for STK39, WNK1, or WNK4 (paired, all F1,38<5.1 and all P > .20; unpaired, all F1,75<4.11 and all P > .32). In contrast, the mean expression level of OXSR1 mRNA (Figure 1C) was significantly (paired, F1,38 = 54.3 and P < .001; unpaired, F1,75 = 38.1 and P < .001) 19.4% greater in the subjects with schizophrenia. In addition, mean WNK3-1 mRNA levels (Figure 1D) were significantly (paired, F1,38 = 50.9 and P < .001; unpaired, F1,75 = 45.6 and P < .001) 48.7% greater in the subjects with schizophrenia. Relative to their matched healthy comparison subjects, OXSR1 and WNK3-1 mRNA levels were higher in 41 and 37, respectively, of the 42 subjects with schizophrenia (Figure 1C and D). None of the covariates (age, sex, PMI, RIN, brain pH, or freezer storage time) were significant in any of the analyses for OXSR1 and WNK3-1 mRNA (paired, all F1,38<2.69 and all P > .11; unpaired, all F1,75<3.76 and all P > .06).